This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL), which is a form of non-Hodgkin lymphoma. The study is specifically for patients whose DLBCL has returned or has not responded to previous treatments. The trial will compare two different treatment combinations. One group will receive a combination of Epcoritamab, a type of medication known as a bispecific antibody, and Lenalidomide, which is taken orally in capsule form. The other group will receive a combination of Rituximab, Gemcitabine, and Oxaliplatin, all of which are given through intravenous infusion.
The purpose of this study is to determine if the combination of Epcoritamab and Lenalidomide can improve the time patients live without their disease getting worse, compared to the combination of Rituximab, Gemcitabine, and Oxaliplatin. Participants will be randomly assigned to one of the two treatment groups. The study will involve regular visits to the clinic for treatment and monitoring, which will include various tests and assessments to track the progress of the disease and the effects of the treatment.
Throughout the study, participants will receive either the active treatment or a placebo, depending on the group they are assigned to. The trial will continue for a set period, during which the health and response to treatment of the participants will be closely monitored by the medical team. The study aims to provide valuable information that could lead to better treatment options for patients with relapsed or refractory DLBCL.
Belgium 
Bulgaria 
Croatia 
Czechia 
France 
Greece 
Hungary 
Poland 
Portugal 
Romania 
The Netherlands 
